Sumitomo Pharma Co., Ltd.
DNPUF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.11 | -0.00 | 0.02 | 25.29 |
| FCF Yield | 1.22% | -164.47% | -0.24% | 3.59% |
| EV / EBITDA | 14.67 | -1.75 | -150.85 | 5.70 |
| Quality | ||||
| ROIC | 3.65% | -50.76% | -18.22% | 2.79% |
| Gross Margin | 61.53% | 59.76% | 67.79% | 71.94% |
| Cash Conversion Ratio | 0.70 | 0.77 | -0.12 | 0.77 |
| Growth | ||||
| Revenue 3-Year CAGR | -10.46% | -17.49% | 2.50% | 5.08% |
| Free Cash Flow Growth | 101.35% | -31,902.86% | -104.54% | -85.78% |
| Safety | ||||
| Net Debt / EBITDA | 7.32 | -1.26 | -54.67 | 0.67 |
| Interest Coverage | 1.11 | -82.97 | -24.37 | 19.75 |
| Efficiency | ||||
| Inventory Turnover | 1.63 | 1.10 | 1.90 | 1.59 |
| Cash Conversion Cycle | 200.94 | 231.36 | 149.23 | 221.42 |